stoxline Quote Chart Rank Option Currency Glossary
Karyopharm Therapeutics Inc. (KPTI)
1.38  0.28 (25.45%)    04-17 16:00
Open: 1.19
High: 1.38
Volume: 3,148,955
Pre. Close: 1.1
Low: 1.145
Market Cap: 161(M)
Technical analysis
2024-04-17 4:47:52 PM
Short term     
Mid term     
Targets 6-month :  1.92 1-year :  2.25
Resists First :  1.64 Second :  1.92
Pivot price 1.33
Supports First :  1.26 Second :  1.02
MAs MA(5) :  1.23 MA(20) :  1.35
MA(100) :  1.09 MA(250) :  1.47
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  23.5 D(3) :  14.1
RSI RSI(14): 52.6
52-week High :  4.11 Low :  0.61
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KPTI ] has closed below upper band by 41.8%. Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.4
Low: 1.13 - 1.14 1.14 - 1.14
Close: 1.36 - 1.38 1.38 - 1.39
Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Headline News

Wed, 17 Apr 2024
37938 Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Purchased by Bleakley Financial Group LLC - Defense World

Mon, 15 Apr 2024
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies UK

Sun, 14 Apr 2024
Does Karyopharm Therapeutics (NASDAQ:KPTI) Have A Healthy Balance Sheet? - Yahoo Movies Canada

Tue, 02 Apr 2024
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders are up 14% this past week, but still in the red over the last three years - Simply Wall St

Mon, 01 Apr 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Mon, 04 Mar 2024
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 115 (M)
Shares Float 105 (M)
Held by Insiders 5.9 (%)
Held by Institutions 67.3 (%)
Shares Short 22,950 (K)
Shares Short P.Month 23,440 (K)
Stock Financials
EPS -1.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.18
Profit Margin -98 %
Operating Margin -112.1 %
Return on Assets (ttm) -27.1 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0.5 %
Gross Profit (p.s.) 0
Sales Per Share 1.26
EBITDA (p.s.) -1.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -93 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -1.11
PEG Ratio 0
Price to Book value -1.17
Price to Sales 1.08
Price to Cash Flow -1.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android